Overall, these results highlighted the complex role of PPARγ in lung carcinogenesis, characterized by increased expression but reduced functional activity during tumor progression, and demonstrated the therapeutic potential of pioglitazone in restoring PPARγ signaling and suppressing tumor development [69]. Here, PPARG is linked to neoplasm.